Cart
sales@molnova.com
Povorcitinib phosphate
CAS No. 1637677-33-8
Povorcitinib phosphate( —— )
Catalog No. M28210 CAS No. 1637677-33-8
Povorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 130 | In Stock |
|
| 5MG | 98 | In Stock |
|
| 10MG | 148 | In Stock |
|
| 25MG | 250 | In Stock |
|
| 50MG | 351 | In Stock |
|
| 100MG | 476 | In Stock |
|
| 200MG | 642 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePovorcitinib phosphate
-
NoteResearch use only, not for human use.
-
Brief DescriptionPovorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.
-
DescriptionPovorcitinib phosphate is a selective JAK1 inhibitor and can be used in studies about the treatment of cutaneous lupus erythematosus and Lichen planus.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayAngiogenesis
-
TargetJAK
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1637677-33-8
-
Formula Weight605.45
-
Molecular FormulaC23H25F5N7O5P
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 100 mg/mL (165.17 mM)
-
SMILESO=P(O)(O)O.N#CCC1(N2C=C(C(C(C)=NN3)=C3C)C=N2)CN(C(C=C(F)C(C(N[C@@H](C)C(F)(F)F)=O)=C4)=C4F)C1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Dhopeshwarkar AS, Nicholson RA. Benzophenanthridine alkaloid, piperonyl butoxide and (S)-methoprene action at the cannabinoid-1 receptor (CB1-receptor) pathway of mouse brain: Interference with [(3)H]CP55940 and [(3)H]SR141716A binding and modification of WIN55212-2-dependent inhibition of synaptosomal l-glutamate release. Eur J Pharmacol. 2014 Jan 15;723:431-41.
molnova catalog
related products
-
CEP-33779
CEP-33779 is a novel, selective, and orally bioavailable inhibitor of JAK2 with an IC50 of 1.8±0.6 nM.
-
S-Ruxolitinib
Ruxolitinib (INCB018424) is the first potent selective JAK1/2 inhibitor to enter the clinic with IC50 of 3.3 nM/2.8 nM in cell-free assays.
-
Ruxolitinib phosphat...
A potent, selective, orally active JAK1/JAK2 inhibitor with IC50 of 3.3/2.8 nM, respectively.
